Cooper Companies (COO) shares were hammered on Thursday after the medtech's fiscal third-quarter sales, specifically its CooperVision segment, lagged Wall Street's expectations by 4.5%. The company attributed the miss to destocking and subsequently opted against selling its CooperSurgical business, leading to a guidance cut.